WASHINGTON — If there was any hope that Congress might overhaul the way this country doles out the patents drug makers get for their new medicines as part of its efforts to drive down drug costs, Tuesday’s Senate Judiciary Committee hearing on the issue issue quashed it.

The hearing began with an admonition from the committee’s chairman, Sen. Lindsey Graham (R-S.C.), that Congress would “do something on patents and prescription drugs this year.” But lawmakers seemed more eager to talk Tuesday about peripheral tweaks to the patent system — or issues entirely unrelated to patents — than about the kind of fundamental reforms that would make it harder for drug makers to file hundreds of patents to shield an expensive drug from competition.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Trying to limit the number of patents granted in one approach. But putting compulsory licenses on the table is another.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy